Panacea Biotec Limited (NSE:PANACEABIO)

DFS Statistics

Total Valuation

Panacea Biotec has a market cap or net worth of INR 24.59 billion. The enterprise value is 23.67 billion.

Market Cap	24.59B
Enterprise Value	23.67B

Important Dates

The next estimated earnings date is Friday, August 8, 2025.

Earnings Date	Aug 8, 2025
Ex-Dividend Date	n/a

Share Statistics

Panacea Biotec has 61.25 million shares outstanding. The number of shares has decreased by -0.25% in one year.

Current Share Class	61.25M
Shares Outstanding	61.25M
Shares Change (YoY)	-0.25%
Shares Change (QoQ)	-0.19%
Owned by Insiders (%)	68.71%
Owned by Institutions (%)	0.07%
Float	15.41M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	4.40
PB Ratio	2.96
P/TBV Ratio	3.10
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-282.74
EV / Sales	4.23
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-30.47

Financial Position

The company has a current ratio of 1.49, with a Debt / Equity ratio of 0.03.

Current Ratio	1.49
Quick Ratio	0.50
Debt / Equity	0.03
Debt / EBITDA	n/a
Debt / FCF	-0.29
Interest Coverage	-15.65

Financial Efficiency

Return on equity (ROE) is -1.05% and return on invested capital (ROIC) is -4.43%.

Return on Equity (ROE)	-1.05%
Return on Assets (ROA)	-3.00%
Return on Invested Capital (ROIC)	-4.43%
Return on Capital Employed (ROCE)	-6.58%
Revenue Per Employee	2.89M
Profits Per Employee	-43,233
Employee Count	1,936
Asset Turnover	0.44
Inventory Turnover	1.02

Taxes

In the past 12 months, Panacea Biotec has paid 7.70 million in taxes.

Income Tax	7.70M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +177.79% in the last 52 weeks. The beta is 0.34, so Panacea Biotec's price volatility has been lower than the market average.

Beta (5Y)	0.34
52-Week Price Change	+177.79%
50-Day Moving Average	439.98
200-Day Moving Average	422.50
Relative Strength Index (RSI)	41.20
Average Volume (20 Days)	177,641

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Panacea Biotec had revenue of INR 5.59 billion and -83.70 million in losses. Loss per share was -1.37.

Revenue	5.59B
Gross Profit	3.60B
Operating Income	-607.20M
Pretax Income	-79.50M
Net Income	-83.70M
EBITDA	-259.10M
EBIT	-607.20M
Loss Per Share	-1.37

Balance Sheet

The company has 1.10 billion in cash and 222.10 million in debt, giving a net cash position of 879.10 million or 14.35 per share.

Cash & Cash Equivalents	1.10B
Total Debt	222.10M
Net Cash	879.10M
Net Cash Per Share	14.35
Equity (Book Value)	8.31B
Book Value Per Share	136.92
Working Capital	1.78B

Cash Flow

In the last 12 months, operating cash flow was -273.70 million and capital expenditures -503.10 million, giving a free cash flow of -776.80 million.

Operating Cash Flow	-273.70M
Capital Expenditures	-503.10M
Free Cash Flow	-776.80M
FCF Per Share	-12.68

Margins

Gross margin is 64.31%, with operating and profit margins of -10.86% and -1.50%.

Gross Margin	64.31%
Operating Margin	-10.86%
Pretax Margin	-1.42%
Profit Margin	-1.50%
EBITDA Margin	-4.63%
EBIT Margin	-10.86%
FCF Margin	n/a

Dividends & Yields

Panacea Biotec does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.25%
Shareholder Yield	n/a
Earnings Yield	-0.34%
FCF Yield	-3.16%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1